Redmile Group’s iShares Biotechnology ETF IBB Stock Holding History

Redmile Group’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-24,000	Closed	-$2.06M	–	59
2014 Q2	$2.06M	Buy	+24,000	New	+$1.89M	0.25%	42

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Redmile Group's IBB Position: Q1 2017 in Review

Redmile Group sold out of iShares Biotechnology ETF (IBB) in Q1 2017, closing a stake of 13,500 shares — an estimated $1.19M sold.

Redmile Group first reported a position in IBB in Q2 2013 and held it in 5 quarters. The position peaked at $1.19M in Q4 2016. 521 funds tracked by Wall St. Rank hold IBB as of Q1 2017.

Redmile Group reported no remaining iShares Biotechnology ETF position as of Q1 2017 after selling out during the quarter.
Redmile Group sold 13,500 iShares Biotechnology ETF shares in Q1 2017, an estimated $1.19M.
Redmile Group first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 5 quarters.
Redmile Group's iShares Biotechnology ETF position peaked at $1.19M in Q4 2016.
521 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2017.

Based on Redmile Group's 13F filing for Q1 2017, filed 15 May 2017.